Blood Cancer
Haematology is the study of blood, blood diseases, and blood-forming tissues and organs. Haematologists focus on the diagnosis, treatment and prevention of blood-related disorders and malignancies. They also focus on diseases of the bone marrow and lymphatic organs such as the lymph node, thymus, spleen, and tonsils which are fed by blood cells and are crucial for the body’s immune response.
For over three decades, Janssen has dedicated itself to advancing research and solutions to meet the needs of people with haematological malignancies. Our goal is to not only make blood-related conditions treatable, but ultimately preventable and curable.
At Janssen, strong collaborations are essential to pioneering innovative solutions in the field of haematology and change the way blood-related conditions are diagnosed and treated. We work side-by-side with specialists, researchers and patient advocacy groups across Europe to deliver the best possible outcome by providing a platform for knowledge exchange and innovation.
In 2019, we introduced the Haematology Outcomes Network in Europe (HONEUR), a collaborative network that partners with data centres across Europe. HONEUR enables us to share real-world data to further develop our knowledge of blood malignancies and offer patients the best treatment possible.
For us, the patient is at the heart of everything we do. We don’t just want to offer solutions. We also want to improve the visibility of blood-related conditions and achieve better outcomes by working together with people and organisations close to patients and their loved ones. By increasing awareness and understanding of those affected by hematologic malignancies, we can enhance support for them and further drive drug development and breakthrough medical therapies and technologies.
Explore our Disease Areas
Acute Myeloid Leukaemia is a rare, fast-acting form of blood cancer that develops in the bone marrow and affects immature white blood cells that would usually grow into various healthy blood cells. In AML, these abnormal blood cells do not mature and instead replicate and replace healthy cells, keeping important organs from functioning, thereby weakening the immune and healing processes.9
Chronic Lymphocytic Leukaemia is a slow-growing cancer of the blood and bone marrow, which results in incompetent, small white blood cells that compromise the immune system. CLL is one of the most common types of leukaemia in Western countries, accounting for 25% of all diagnoses.10 There are instances in which CLL is used as an overarching term that includes Small Lymphocytic Lymphoma (SLL) because they are both nearly the same disease, however CLL is commonly detected in the blood and bone marrow, whereas SLL is primarily detected in the lymph nodes.11
Mantle Cell Lymphoma is an aggressive type of blood cancer that develops in the outer part of the lymph node, an essential part of the immune system.12 Affecting only 1 in 100,000 people, MCL is a very rare cancer.13
Multiple Myeloma is a rare, slow-growing cancer of the white blood cells that weakens the immune system and inhibits important organs from functioning.14 In those with MM, mutated white blood cells last longer and multiply rapidly, taking up space in the bloodstream and crowding out healthy cells.14
Myelodysplastic Syndromes are a group of rare, slow-growing blood disorders in which blood cells are misprinted, making them unable to do their job properly.15 MDS subtypes are categorized by the specific type of blood cell affected and vary in rarity.16
Waldenström's Macroglobulinemia is a rare and slow-growing cancer of the white blood cells. It mostly grows in the bone marrow, slowing down the growth of blood cells which can lead to anaemia and a weakened immune system.17